New Study Demonstrates the Amazing Benefits of Longvida® Curcumin.
The results of an exciting new study conducted on healthy middle-aged people has shown the remarkable effects of Longvida® curcumin in producing several health-promoting effects, while also reducing critical disease markers. Results from a 30-day placebo-controlled randomized trial showed a single capsule of Longvida® (containing a relatively low dose of 80 mg curcumin) significantly improved a number of markers, including plasma amyloid-beta (which is implicated in the development of Alzheimers disease) and a range of inflammatory and oxidative markers. This study, performed by Dr. Robert DiSilvestro, Ph.D., Professor in the Department of Human Nutrition at Ohio State University, was published on September 26 in Nutrition Journal.
This is the first placebo-controlled clinical trial to show that a nutritional intervention can lower plasma amyloid-beta in healthy, middle-aged humans. Along with a decreased risk of cardiovascular disease and improved liver health markers, both direct and indirect antioxidant actions of curcumin were also evident in the subjects; these findings are consistent with in vitro and animal studies used to measure increases in curcumin-induced antioxidant enzyme activity.
The results of the study suggest that curcumin can produce beneficial effects in people who do not have any known diseases. Given that the study was conducted for only 30 days, one would expect even better results with a study of longer duration.
Longvida®, a highly bioavailable form of curcumin, is the result of testing over two hundred formulations and has taken more than ten years to develop. In a human study on cancer patients, Longvida® curcumin was shown to be over 100 times more bioavailable than regular curcumin. This formulation was developed and patented by UCLA Medical School and is licensed exclusively in Canada to Calgary’s Advanced Orthomolecular Research (AOR). Longvida® CurcuVIVA is used in our Brain Protection Add-On Pack.